Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 12

Platelet distribution width as a prognostic factor in patients with COPD – pilot study

Authors Białas AJ, Pedone C, Piotrowski WJ, Antonelli Incalzi R

Received 7 January 2017

Accepted for publication 30 May 2017

Published 1 August 2017 Volume 2017:12 Pages 2261—2267

DOI https://doi.org/10.2147/COPD.S131868

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 4

Editor who approved publication: Dr Richard Russell

Adam J Białas,1,2,* Claudio Pedone,3,* Wojciech J Piotrowski,1,2 Raffaele Antonelli Incalzi3

1Department of Pneumology and Allergy, Medical University of Lodz, Łódź, Poland; 2Healthy Aging Research Centre (HARC), Medical University of Lodz, Łódź, Poland; 3Department of Geriatrics, Campus Bio-Medico University of Rome, Rome, Italy

*These authors contributed equally to this work

Background: Platelets may actively participate in inflammation in COPD. Platelet distribution width (PDW), a measure of platelets’ volume heterogeneity, may increase in platelets’ activation. We hypothesized that PDW may be a marker of hypercoagulation, which plays a significant role in conditions associated with worse survival of patients with COPD, eg, acute myocardial infarction and other forms of ischemic heart disease.
Methods: Retrospective analysis of 79 patients. Variables were compared after grouping patients according to the upper normal limit of PDW, using Welch’s t-tests or Mann–Whitney U, and chi-square tests. Survival in the two groups was compared using the Kaplan–Meier method and Cox proportional hazards regression.
Results: Ten patients presented values of PDW above 16 fL, which was the upper limit of normality for our laboratory. Compared to patients with normal PDW, they had lower forced expiratory flow between 25% and 75% of vital capacity (FEF 25–75) – 35% of reference value vs 57% (P=0.003) and peak expiratory flow – 39% vs 54% (P<0.001). The median survival of patients with elevated PDW was 743 days compared to those with normal PDW (1,305 days) (P=0.025). The adjusted HR was 4.59 (95% CI: 1.1, 19.19; P=0.04).
Conclusion: Our analysis indicates that elevated PDW is associated with reduced survival of patients with COPD. If our data are to be confirmed, PDW may be used as an inexpensive and repeatable prognostic tool in COPD.

Keywords: COPD, PDW, platelets, inflammation, survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Geroprotectors as a therapeutic strategy for COPD – where are we now?

Miłkowska-Dymanowska J, Białas AJ, Makowska J, Wardzynska A, Górski P, Piotrowski WJ

Clinical Interventions in Aging 2017, 12:1811-1817

Published Date: 24 October 2017